Engineered Cells with Reduced Gene Expression for Viral Production

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current vaccine production methods are costly and time-consuming, limiting global immunization coverage due to high bioproduction expenses and lengthy processes.

Innovation Solution

Infecting cells with viruses while reducing the expression of specific cellular genes such as BTN2A1, CNTD2, COQ9, EMX2, EP300, FGF2, GCGR, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, SEC61G, STRADA, SVOPL, ZFYVE9, and ZNF205 to enhance viral production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional vaccine production methods are used, then vaccine production can be achieved, but production costs are high and time consumption is excessive

Engineering Contradiction:

Improvevaccine production efficiencyVSAvoidtime required for vaccine production

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent applies parameter changes by modifying the expression levels of specific host cell genes (such as BTN2A1, CNTD2, COQ9, EMX2, EP300, FGF2, GCGR, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, SEC61G, STRADA, SVOPL, ZFYVE9, and ZNF205) to optimize viral replication parameters. By reducing the expression of these cellular genes, the patent achieves enhanced viral production kinetics and increased viral titers, thereby improving vaccine production efficiency and reducing production time

Inventive Principle:

Principle #35Parameter changes

2Productivity

If conventional vaccine production methods are used, then vaccine production can be achieved, but production costs are high

Engineering Contradiction:

Improvevaccine production efficiencyVSAvoidproduction cost

Core Design Contradiction:

ProductivityVSEase of manufacture

Solution Approach 1:

The patent modifies cellular gene expression parameters to enhance viral production yields. By reducing the expression of specific host genes that limit viral replication, the patent achieves higher viral titers per unit of cell culture, thereby reducing the overall cost of vaccine production through improved manufacturing efficiency

Inventive Principle:

Principle #35Parameter changes

3Productivity

If viral production is increased through gene expression modulation, then vaccine production efficiency is enhanced, but cellular function may be compromised

Engineering Contradiction:

Improveviral productionVSAvoidcellular function stability

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent extracts and removes specific limiting factors from the host cell system by reducing the expression of genes (BTN2A1, CNTD2, COQ9, EMX2, EP300, FGF2, GCGR, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, SEC61G, STRADA, SVOPL, ZFYVE9, and ZNF205) that negatively impact viral replication. This selective removal of constraints enhances viral production without requiring comprehensive modification of cellular functions

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent applies local quality changes by specifically targeting and modulating the expression of individual genes that have been identified as limiting viral production, rather than globally altering cellular function. This localized approach allows enhanced viral replication in specific pathways while maintaining overall cellular stability and reliability

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS11655471B2Engineered cells with decreased gene expression resulting in increased viral production

Publication Date: 2023.05.23 UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC

AI summary

Disclosed are compositions and methods for increasing virus production. In particular, disclosed herein are cell or cell line comprises reduced expression of one or more cellular genes selected from the group comprising COQ9, FGF2, NAT9, NDUFA9, NEU2, PLA2G1B, PYCR1, RAD51AP1, STRADA, SVOPL, and/or ZFYVE9 for use in increasing viral production.